AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

A-32 Cell Therapy for Neurogenic Bladder

Technology Benefits: ΓùÅ Excellent therapeutic effect for sever neurogenic bladderΓùÅ Minimal invasionΓùÅ Long-lasting therapy

Technology Application: Therapy for neurogenic bladder

Detailed Technology Description: None

Supplementary Information: Inventor: YAMAMOTO Tokunori | KOIDE Naoshi | TAKEI Yoshifumi | MATSUKAWA Yoshihisa | FUNAHASHI Yasuhito | GOTOH Momokazu
Priority Number: WO2011043147A1
IPC Current: A61K003512 | A61P001302 | A61P001510 | A61P004300 | C12N00050775
Assignee Applicant: National University Corporation Nagoya University
Title: CELL PREPARATION FOR ERECTILE DYSFUNCTION OR URINARY INCONTINENCE CONTAINING ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS | PRÉPARATION CELLULAIRE CONTRE LE DYSFONCTIONNEMENT ÉRECTILE OU L'INCONTINENCE URINAIRE, CONTENANT DES CELLULES SOUCHES MÉSENCHYMAT
Usefulness: CELL PREPARATION FOR ERECTILE DYSFUNCTION OR URINARY INCONTINENCE CONTAINING ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS | PRÉPARATION CELLULAIRE CONTRE LE DYSFONCTIONNEMENT ÉRECTILE OU L'INCONTINENCE URINAIRE, CONTENANT DES CELLULES SOUCHES MÉSENCHYMATEUSES ISSUES DU TISSU ADIPEUX
Summary: The cell formulation is useful for treating erectile dysfunction and urinary incontinence (claimed).
Novelty: Cell formulation useful for treating erectile dysfunction and urinary incontinence, comprises fat-tissue derived mesenchymal stem cell

Industry: Biomedical

Sub Category: Medical Composition

*Abstract: Researchers at Nagoya University have developed a novel medical use of adipose-derived mecsenchymal stem cells (ADSCs) for neurogenic bladder therapy. Neurogenic bladder affects both males and females, and results from various causes, including delivery, aging, and pelvic surgery, and for which there are currently no effective and minimal invasive therapies. Radical prostatectomy is most common pelvic surgery, and occurs neurogenic bladder after the surgery. The researchers injected cell preparations containing ADSCs into periurethral regions of postoperative patients, and confirmed that these treatments dramatically helped the patients recover from neurogenic bladder. The present technology may be applicable as a novel therapy for severe neurogenic bladder.

Country/Region: USA

For more information, please click Here